ArticleJournal of the American Heart Association2025
Novel Risk Score to Predict Poor Outcome After Endovascular Treatment in Anterior Circulation Occlusive Acute Ischemic Stroke.
Article in Journal of the American Heart Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Thrombus Metabolism-Based Molecular Subtyping for Prognostic Risk Stratification in Acute Ischemic Stroke: A Preliminary Study.CNS neuroscience & therapeutics · 2026Article
- Combined assessment of ASPECTS and collateral status predict outcomes after endovascular therapy in patients with large ischemic stroke.Frontiers in neurology · 2026Observational
- Contrast extravasation on Dyna-CT as a predictor of malignant brain edema after mechanical thrombectomy for acute anterior circulation large vessel occlusion.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to develop and validate a prognostic score to predict outcomes after endovascular treatment in acute ischemic stroke.
methodsThe prognostic score was developed based on the ACTUAL (Endovascular Treatment for Acute Anterior Circulation Ischemic Stroke) registry. The validation cohort was derived from the Captor trial. Independent predictors of poor outcome after endovascular treatment were obtained from the least absolute shrinkage and selection operator regression and multivariable logistic regression. Corresponding regression coefficients were used to generate point scoring system. The area under the receiver operating characteristic curve and the Hosmer-Lemeshow goodness-of-fit test were used to assess model discrimination and calibration. The predictive properties of the developed prognostic score were validated and the discriminative power was compared with other validated tools.
resultsA 17-point Age, Collateral Status, Blood glucose, Alberta Stroke Program Early Computed Tomography Score, and National Institutes of Health Stroke Scale score scale was developed from the set of independent predictors, including age, admission National Institutes of Health Stroke Scale score, Alberta Stroke Program Early Computed Tomography Score on initial computed tomography scan, blood glucose, and collateral status. The scale showed good discrimination in the derivation cohort (area under the receiver operating characteristic curve, 0.79 [95% CI, 0.75-0.82]) and validation cohorts (area under the receiver operating characteristic curve, 0.77 [95% CI, 0.70-0.84]). The scale was well calibrated (Hosmer-Lemeshow test) in the derivation cohort (
conclusionsThe Age, Collateral Status, Blood glucose, Alberta Stroke Program Early Computed Tomography score, and National Institutes of Health Stroke Scale score scale is a valid tool for predicting outcomes and may be useful for endovascular stroke treatment in anterior circulation large vessel occlusions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.